PACIFIC BIOSCIENCES OF CALIFORNIA, INC.PACBEarnings & Financial Report
Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.
PACB Q4 FY2025 Key Financial Metrics
Revenue
$44.6M
Gross Profit
$16.6M
Operating Profit
$-41.2M
Net Profit
$-40.4M
Gross Margin
37.1%
Operating Margin
-92.3%
Net Margin
-90.4%
YoY Growth
13.8%
EPS
$-0.11
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Q4 FY2025 Financial Summary
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported revenue of $44.6M (up 13.8% YoY) for Q4 FY2025, with a net profit of $-40.4M (down 1802.7% YoY) (-90.4% margin). Cost of goods sold was $28.1M, operating expenses totaled $57.8M.
Key Financial Metrics
| Total Revenue | $44.6M |
|---|---|
| Net Profit | $-40.4M |
| Gross Margin | 37.1% |
| Operating Margin | -92.3% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Q4 FY2025 revenue of $44.6M breaks down across 2 segments, led by Products at $39.0M (87.3% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Products | $39.0M | 87.3% |
| Service And Other | $5.7M | 12.7% |
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Revenue by Segment — Quarterly Trend
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as Products and Service And Other) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Products | $39.0M | $32.6M | $33.1M | $31.1M |
| Service And Other | $5.7M | $5.8M | $6.7M | $6.0M |
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Annual Revenue by Year
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $160.0M).
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Quarterly Revenue & Net Profit History
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $44.6M | +13.8% | $-40.4M | -90.4% |
| Q3 FY2025 | $38.4M | -3.8% | $-38.0M | -98.9% |
| Q2 FY2025 | $39.8M | +10.4% | $-41.9M | -105.4% |
| Q1 FY2025 | $37.2M | -4.3% | $-426.1M | -1146.8% |
| Q4 FY2024 | $39.2M | — | $2.4M | 6.0% |
| Q3 FY2024 | $40.0M | -28.2% | $-60.7M | -151.9% |
| Q2 FY2024 | $36.0M | -24.3% | $-173.3M | -481.3% |
| Q1 FY2024 | $38.8M | -0.2% | $-78.2M | -201.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $38.8M | $36.0M | $40.0M | $39.2M | $37.2M | $39.8M | $38.4M | $44.6M |
| YoY Growth | -0.2% | -24.3% | -28.2% | N/A | -4.3% | 10.4% | -3.8% | 13.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.67B | $1.51B | $1.45B | $1.26B | $860.8M | $825.5M | $803.2M | $784.1M |
| Liabilities | $1.02B | $1.02B | $996.9M | $753.9M | $769.2M | $764.0M | $767.1M | $778.7M |
| Equity | $649.0M | $492.7M | $453.1M | $506.6M | $91.6M | $61.5M | $36.1M | $5.3M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-75.7M | $-54.3M | $-45.5M | $-30.6M | $-44.1M | $-29.4M | $-18.7M | $-19.1M |